MX2013008175A - Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos. - Google Patents

Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos.

Info

Publication number
MX2013008175A
MX2013008175A MX2013008175A MX2013008175A MX2013008175A MX 2013008175 A MX2013008175 A MX 2013008175A MX 2013008175 A MX2013008175 A MX 2013008175A MX 2013008175 A MX2013008175 A MX 2013008175A MX 2013008175 A MX2013008175 A MX 2013008175A
Authority
MX
Mexico
Prior art keywords
photosensitizers
pharmaceutical compositions
topical delivery
photoâ
lemuteporfin
Prior art date
Application number
MX2013008175A
Other languages
English (en)
Inventor
Jerome A Morris
Deepank Utkhede
David W C Hunt
Original Assignee
Quadra Logic Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadra Logic Tech Inc filed Critical Quadra Logic Tech Inc
Publication of MX2013008175A publication Critical patent/MX2013008175A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención incluye y proporciona composiciones que comprenden agentes fotosensibilizadores, en particular, lemuteporfina, y su uso en terapia foto-dinámica para el tratamiento de condiciones dermatológicas.
MX2013008175A 2011-01-13 2012-01-13 Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos. MX2013008175A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161432453P 2011-01-13 2011-01-13
PCT/US2012/021263 WO2012097264A2 (en) 2011-01-13 2012-01-13 Pharmaceutical compositions for topical delivery of photosensitizers and uses thereof

Publications (1)

Publication Number Publication Date
MX2013008175A true MX2013008175A (es) 2013-12-16

Family

ID=45563542

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008175A MX2013008175A (es) 2011-01-13 2012-01-13 Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos.

Country Status (10)

Country Link
US (1) US20130289089A1 (es)
EP (1) EP2663285A2 (es)
JP (1) JP5964322B2 (es)
KR (1) KR20140089478A (es)
CN (1) CN103607999A (es)
AU (1) AU2012205410A1 (es)
BR (1) BR112013017953A2 (es)
CA (1) CA2824768A1 (es)
MX (1) MX2013008175A (es)
WO (1) WO2012097264A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2561729C2 (ru) 2009-07-08 2015-09-10 Дермира (Канада), Инк. Аналоги tofa, применимые при лечении дерматологических расстройств или состояний
JP2015522079A (ja) * 2012-07-11 2015-08-03 ダーミラ, インク.Dermira, Inc. 光線感作物質の局所送達のための医薬組成物及びその使用
ES2636466T3 (es) 2013-05-31 2017-10-05 Lm Wp Patent Holding A/S Sistema y método para ayudar en la fabricación de una cubierta de pala de turbina eólica
EP3362145B1 (en) 2015-10-15 2021-01-06 DUSA Pharmaceuticals, Inc. Adjustable illuminator for photodynamic therapy and diagnosis
US10603508B2 (en) 2015-10-15 2020-03-31 Dusa Pharmaceuticals, Inc. Adjustable illuminators and methods for photodynamic therapy and diagnosis
WO2018148795A1 (en) * 2017-02-15 2018-08-23 Botanix Pharmaceuticals Ltd Compositions for treating acne
EP3582763A4 (en) * 2017-02-15 2020-11-25 Botanix Pharmaceuticals Ltd COMPOSITIONS FOR THE TREATMENT OF ACNE
EP3655035A4 (en) * 2017-07-17 2021-04-14 Andrea Willey PHOTODYNAMIC THERAPY PROCEDURE FOR SKIN DISEASES
US10357567B1 (en) 2018-01-12 2019-07-23 Dusa Pharmaceuticals, Inc. Methods for photodynamic therapy

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0774145B2 (ja) * 1986-12-15 1995-08-09 株式会社資生堂 結晶性薬物含有乳化組成物
US4883790A (en) 1987-01-20 1989-11-28 University Of British Columbia Wavelength-specific cytotoxic agents
US4920143A (en) 1987-04-23 1990-04-24 University Of British Columbia Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
US5095030A (en) 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US5171749A (en) 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US5283255A (en) 1987-01-20 1994-02-01 The University Of British Columbia Wavelength-specific cytotoxic agents
GB8805849D0 (en) 1988-03-11 1988-04-13 Efamol Holdings Porphyrins & cancer treatment
GB9207988D0 (en) * 1992-04-10 1992-05-27 Smithkline Beecham Plc Topical composition
GB9513572D0 (en) 1995-07-04 1995-09-06 Ag Patents Ltd Infusion container
US5880145A (en) 1997-05-07 1999-03-09 The University Of British Columbia Class of benzoporphyrin derivative photoactive compounds
ES2210740T3 (es) 1997-05-07 2004-07-01 University Of British Columbia Nueva clase de compuestos fotoactivos derivados de la benzoporfirina.
CA2284879C (en) 1997-05-07 2005-10-25 Qlt Phototherapeutics, Inc. Ethylene glycol esters of monohydrobenzoporphyrin derivatives as photoactive agents
US5954703A (en) * 1997-10-31 1999-09-21 Dusa Pharmaceuticals, Inc. Method and apparatus for applying 5-aminolevulinic acid
US6004821A (en) 1998-03-07 1999-12-21 Levine; Robert A. Method and apparatus for performing chemical, qualitative, quantitative, and semi-quantitative analyses of a urine sample
US6223071B1 (en) 1998-05-01 2001-04-24 Dusa Pharmaceuticals Inc. Illuminator for photodynamic therapy and diagnosis which produces substantially uniform intensity visible light
SE9801705D0 (sv) * 1998-05-14 1998-05-14 Bioglan Ab Biologically active composition
US6887260B1 (en) * 1998-11-30 2005-05-03 Light Bioscience, Llc Method and apparatus for acne treatment
MY138222A (en) 1999-07-19 2009-05-29 Thomson Licensing Sa Tuning system for achieving rapid signal acquisition for a digital satellite receiver
IL133253A0 (en) 1999-12-01 2001-04-30 Yeda Res & Dev Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
GB0018528D0 (en) 2000-07-27 2000-09-13 Photocure Asa Compounds
CA2422865C (en) * 2000-08-16 2012-10-16 The General Hospital Corporation D/B/A Massachusetts General Hospital Aminolevulinic acid photodynamic therapy for treating sebaceous gland disorders
AU2002340659B2 (en) 2001-11-09 2008-04-10 Qlt Inc. Photodynamic therapy for the treatment of hair loss
AU2003230808A1 (en) * 2002-04-05 2003-10-27 Candela Corporation High fluence rate activation of photosensitizers for dermatological applications
CA2457214A1 (en) 2004-02-06 2005-08-06 Qlt Inc. Photodynamic therapy for the treatment of acne
MX2007000338A (es) * 2004-06-09 2007-03-28 Quadra Logic Tech Inc Terapia fotodinamica para el tratamiento de trastornos hiperactivos de glandulas sebaceas.

Also Published As

Publication number Publication date
JP2014505693A (ja) 2014-03-06
WO2012097264A3 (en) 2012-10-18
JP5964322B2 (ja) 2016-08-03
BR112013017953A2 (pt) 2017-08-29
WO2012097264A2 (en) 2012-07-19
NZ613168A (en) 2015-06-26
AU2012205410A1 (en) 2013-08-01
CN103607999A (zh) 2014-02-26
US20130289089A1 (en) 2013-10-31
EP2663285A2 (en) 2013-11-20
CA2824768A1 (en) 2012-07-19
KR20140089478A (ko) 2014-07-15

Similar Documents

Publication Publication Date Title
MX2013008175A (es) Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos.
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
TN2013000508A1 (en) Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
TN2014000175A1 (en) Novel purine derivatives and their use in the treatment of disease
MX346224B (es) Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.
GB201118656D0 (en) New compounds
AU2011328009A8 (en) Compounds and methods for treating pain
IL231168B (en) Benzenesulfonamide history of quinoxaline, their pharmaceutical preparations and their use for the preparation of a drug for the treatment of cancer
JO3366B1 (ar) مثبطات بيرازوليل كوينوكزالين كاينيز
WO2015009726A3 (en) Medical uses of cd38 agonists
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
GB201111485D0 (en) Drug composition and its use in therapy
TN2012000611A1 (en) Formulations of rifaximin and uses thereof
MX343688B (es) Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.
MX349004B (es) Nuevos compuestos.
MX343706B (es) Derivados heterocíclicos novedosos.
AU2012253759A8 (en) Tricyclic sulfonamide compounds and methods of making and using same
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
MX346644B (es) Moduladores de receptores canabinoides.
MX2015004362A (es) Derivados de ketamina.
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer